Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy

Rahkola-Soisalo, Päivi; Savolainen-Peltonen, Hanna; Gissler, Mika; Hoti, Fabian; Vattulainen, Pia; Ylikorkala, Olavi; Mikkola, Tomi S.

doi:10.1007/s00192-018-3682-7

Cited by 16 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, there are studies reporting that menopause has no effect on UI (16). However, some studies also report a negative relationship between menopausal status and UI (25). According to the results of our study, there were significant differences in terms of ICIQ-SF scores with 317 (50.9%) participants who did not enter menopause and those with a menopause duration of 5 years or more.…”

Section: Discussionsupporting

confidence: 43%

Women with Hidden Urinary Incontinence Waiting to Be Discovered: A Snapshot From a Developing Country

Aynacı¹

2020

J Basic Clin Health Sci

View full text Add to dashboard Cite

Purpose: Urinary incontinence (UI), is a public health problem that has an increasing frequency and has an impact on the quality of life (QoL) of women worldwide. In this study, in which we focus on the general approach to risk factors associated with urinary incontinence, we aim to address the importance of transferring between practical healthcare services and screening programs.Methods: Our study was conducted between December 2018-August 2019 with patients who admitted to Trakya University Medical Hospital with different gynecologic symptoms. This study investigated the relationship between menopause, incontinence, type of delivery, socioeconomic status, and risk factors. A modular inquiry form-short form (ICIQ-SF) was used for the research in all aspects of urinary incontinence and its impact on the quality of life. Our aim was to increase the awareness of clinics about urinary incontinence.Results: Of the 622 participants, 176 had urinary incontinence symptoms. There was a significant relationship between menopause, age, medical treatment for uriner infection, body mass index, living in rural / urban areas, normal birth rate, education level and urinary incontinence.Conclusion: It's important to assess the effects of urinary incontinence symptoms on women's QoL appropriately in UI-related research and clinical studies. Women with urinary incontinence symptoms should ensure that their body mass index is within the ideal range. In every period, quality of women's life can be improved with the necessary cares. Building awareness about urinary incontinence can help improve treatment-seeking behaviour. Improving the quality of life of women will help to increase the desired levels of quality health and welfare in the management of public health, especially in developing countries.

show abstract

Section: Discussionsupporting

confidence: 43%

Women with Hidden Urinary Incontinence Waiting to Be Discovered: A Snapshot From a Developing Country

Aynacı¹

2020

J Basic Clin Health Sci

View full text Add to dashboard Cite

show abstract

“…Other risks associated with MHT include dementia (in women aged ≥ 60 years) [99], gallbladder disease [100], and urinary incontinence [101].…”

Section: Safety Aspects Of Menopausal Hormone Therapymentioning

confidence: 99%

Update on Menopausal Hormone Therapy for Fracture Prevention

Štěpán

Hruskova

Kverka

2019

Curr Osteoporos Rep

View full text Add to dashboard Cite

Purpose of Review The goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause. Recent Findings Estrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle and cartilage. Estrogen, but not antiresorptive therapies, can attenuate the inflammatory bonemicroenvironment associated with estrogen deficiency. However, already on second year of administration, MHT is associated with excess breast cancer risk, increasing steadily with duration of use. Summary MHT should be considered in women with premature estrogen deficiency and increased risk of bone loss and osteoporotic fractures. However, MHT use for the prevention of bone loss is hindered by increase in breast cancer risk even in women younger than 60 years old or who are within 10 years of menopause onset.

show abstract

“…HRT was long being used as a therapeutic option for treating UI plus symptoms of vulvovaginal atrophy until the results of a systematic review revealed that systemic HRT increases the risk of UI [24], while vaginal estrogen improves this process [26]. An extensive case-control study was conducted in Finland from 1994 to 2011 to investigate the conflicting effects of the topical and systemic forms of estrogen, and the results obtained showed that both topical and systemic forms of hormone therapy exacerbate SUI symptoms [27]. Invasive and surgical measures are considered when conservative management and medication prove ineffective in treating UI [28].…”

Section: Discussionmentioning

confidence: 99%

The Effect of <b><i>Panax ginseng</i></b> on Genitourinary Syndrome in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

et al. 2021

View full text Add to dashboard Cite

Background: Menopause and estrogen deprivation cause a rise in the number of urogenital tract complaints. Objective: This study was conducted to assess the effectiveness of ginseng on genitourinary syndrome. Methods: This randomized trial was conducted on 60 postmenopausal women with genitourinary syndrome. The participants were randomly allocated to ginseng and placebo groups twice daily for 4 weeks. Vaginal maturation index and vaginal pH were evaluated before and 4 weeks after intervention as the primary outcomes. Also, the atrophic vaginitis and incontinence questionnaires were completed before and after intervention as the secondary outcomes. The safety of intervention was assessed by the side effects checklist. Results: No significant differences were observed between the 2 groups in objective symptoms after the intervention, but the difference was statistically significant (p < 0.001) in terms of subjective symptoms of atrophic vaginitis. One case of insomnia and palpitation and 2 cases of hot flashes were reported in the intervention group, and 1 case of gastric discomfort and change in urine appearance was reported in the placebo group. Conclusion: Ginseng only improved the patient-assessed symptoms and had no significant effect on the clinician-assessed outcomes. Further studies are required to determine the precise pharmacological mechanisms of ginseng on genitourinary syndrome.

show abstract

Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy

Abstract: The use of HT regimens may predispose to the de novo development or worsening of pre-existing SUI. Thus, caution is needed when these regimens are prescribed to women with mild stress-related urine leakage or with established SUI risk factors.

Cited by 16 publications

References 26 publications

Women with Hidden Urinary Incontinence Waiting to Be Discovered: A Snapshot From a Developing Country

Women with Hidden Urinary Incontinence Waiting to Be Discovered: A Snapshot From a Developing Country

Update on Menopausal Hormone Therapy for Fracture Prevention

The Effect of <b><i>Panax ginseng</i></b> on Genitourinary Syndrome in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Contact Info

Product

Resources

About